One hundred and forty-one years now have passed since Shiono Gisaburo Shoten, the drug wholesaler that would become Shionogi & Co., Ltd., began operations in Doshomachi, Osaka, in 1878. Since then, Shionogi has evolved into a leading pharmaceutical manufacturer via the development of our first proprietary antibiotic, Shinomin; the launch of Shiomarin, the world’s first oxacephem antibiotic, also developed in-house; and the success of our hyperlipidemia treatment Crestor, which has grown into a blockbuster. From fiscal 2005, the Company identified priority therapeutic areas, concentrating business resources on infectious diseases, pain treatment, and metabolic diseases. From fiscal 2010, we launched the anti-HIV agent Tivicay and other new growth drivers as we succeeded in our transition to a more robust profit-generating business structure.
We aim to achieve further transformation by continuing to address healthcare needs.
|1878||Gisaburo Shiono, Sr., founder of the Company, launched Shiono Gisaburo Shoten as a drug wholesaler at the present site of the head office, Doshomachi, Osaka|
|1886||The management of Shionogi decided to concentrate on imported western drugs|
|1897||Shionogi started to deal directly with trading firms in Europe and the US|
Antacidin, an antacid agent, was launched as the first drug produced
The corporate trademark FUNDOH was registered
|1910||A manufacturing plant, Shiono Seiyakusho, was constructed|
|1919||Shiono Gisaburo Shoten and Shiono Seiyakusho were merged, and the new company was named Shionogi Shoten|
|1922||Established the Kuise plant (now Kuise Site)|
|1924||Established the new head office building in Doshomachi, Osaka|
|1943||The Company was renamed, Shionogi Seiyaku (now Shionogi & Co., Ltd.)|
|1946||Established the Aburahi Laboratories in Shiga (now Aburahi Facilities)|
|1949||Shionogi's shares listed on the Tokyo and Osaka Stock Exchanges|
|1950||Launched analgesic antipyretics, Sedes|
|1953||Launched the multiple vitamins and minerals, Popon-S|
|1957||The Company Policy of Shionogi was established|
Established the modern product detailing system
|1959||Launched sulfamethoxazole, Shinomin|
|1961||Established Shionogi Research Laboratories in Osaka (now integrated into SPRC; Shionogi Pharmaceutical Research Center)|
Started veterinary drug, agricultural chemical and clinical laboratory businesses (divested in 2002, 2001 and 2002, respectively)
Established Taiwan Shionogi & Co., Ltd.
|1964||Began to sponsor the TV program, Shionogi Music Fair|
|1968||Established the Settsu plant in Osaka|
|1976||Established Nichia Pharmaceutical Industries Ltd. (now Shionogi Pharma Chemicals Co., Ltd.)|
|1978||Celebrated our 100th year in business|
Established Shionogi Shibuya building in Tokyo
Established the Development Research Laboratories in Osaka (now SPRC)
|1982||Launched the cephem antibiotic, Shiomarin, in Japan|
|1983||Constructed the Kanegasaki Plant in Iwate|
Established Institute for Medical Science on the Settsu plant property (now integrated into SPRC)
Launched the cephem antibiotic, Flumarin, in Japan
Acquired the capsule business from Eli Lilly (divested in 2005)
Established Shionogi General Service Co., Ltd.
|1993||Opened the new head office building in Doshomachi, Osaka|
|1997||Launched the cephem antibiotic, Flomox, in Japan|
The Shionogi Charter of Conduct was established
Established Ohmori Co., Ltd., a drug wholesaler (divested in 2002)
Established Bushu Pharmaceuticals Ltd. (divested in 2010)
|2000||The 1st Medium-Term Business Plan starts|
Established Shionogi USA, Inc. (now Shionogi Inc.)
Established a joint venture named Shionogi-GlaxoSmithKline Pharmaceutical LLC (later Shionogi-ViiV Healthcare LLC)
|2003||Launched the cancer pain analgesic, OxyContin, in Japan|
The 2nd Medium-Term Business Plan starts
Launched the hyperlipidemia treatment, Crestor, in Japan
Launched the carbapenem antibiotic, Finibax, in Japan
Established Shionogi Analysis Center Co., Ltd.
Launched the cancer pain analgesic, OxiNorm, in Japan
Acquired US-based Sciele Pharma, Inc. (now Shionogi Inc.)
Established a joint research facility with Hokkaido University, Shionogi Innovation Center for Drug Discovery
Launched the hypertension treatment, Irbetan, in Japan
Launched the acne vulgaris treatment, Differin, in Japan
Launched the idiopathic pulmonary fibrosis treatment, Pirespa, in Japan
The 3rd Medium-Term Business Plan starts
Established Shionogi Techno Advance Research Co., Ltd.
Established the PET Molecular Imaging Center at the Osaka University Graduate School of Medicine
Launched the anti-viral drug for influenza, Rapiacta, in Japan
Launched the antidepressant drug, Cymbalta, in Japan
Acquired a Chinese pharmaceutical company, C&O Pharmaceutical Technology (Holdings) Limited
Established a new research facility SPRC4, and integrated several research functions into SPRC
Established a European subsidiary, Shionogi Limited in the UK
New business scheme for the HIV integrase inhibitor franchise products initiated with ViiV Healthcare
Launched the injectable cancer pain analgesic, OxiFast, in Japan
Launched the hypertension treatment, Aimix, in Japan
Established Beijing Shionogi Pharmaceutical Technology Limited in China
Established Shionogi Singapore Pte. Ltd.
Modified the Crestor royalty structure with AstraZeneca
Launched the postmenopausal vulvar and vaginal atrophy treatment, Osphena, in the US
Launched the hypertension treatment, Irtra, in Japan
The Medium-Term Business Plan "SGS2020" starts
Launched the HIV treatment, Tivicay, in Japan
Launched the HIV treatment, Triumeq, in Japan
Launched the desendsitization therapy, Acitair, house dust mite sublingual tablet in Japan
Launched the thrombocytopenia treatment, Mulpleta, in Japan
New Medium-Term Business Plan Update to Shionogi Growth Strategy 2020 (SGS2020)
Established Shionogi Healthcare Co., Ltd.
Launched hyperlipidemia treatment Crestor OD tablets.
Established Shionogi Marketing Solutions Co., Ltd.
Established Shionogi Pharmacovigilance Center Co., Ltd.
Established Shionogi Business Partner Co., Ltd.
Established Shionogi Digital Science Co., Ltd.
Established Shionogi Career Development Center Co., Ltd.
Launched cancer pain treatment Methapain.
Launched ADHD therapeutic agent Intuniv.
Launched opioid-induced constipation (OIC) treatment Symproic.
Launched chronic cancer pain treatment OxyContin TR tablets.
Established Shionogi Pharma Co., Ltd.
Established European subsidiary Shionogi B.V.
Launched flu drug Xofluza.
Launched thrombocytopenia treatment Mulpleta in the US.
Launched anti-HIV agent Juluca.
Established a joint venture Stream-I with M3, Inc.
Made UMN Pharma a consolidated subsidiary.
Established Shionogi Education and Training Center in Amagaski,Hyogo.
Launched opioid-induced constipation (OIC) treatment Rizmoic in Europe.
Launched flu drug Xofluza in Taiwan.
Launched Vivance for attention deficit/hyperactivity disorder (ADHD).
Started the Medium-Term Business Plan, Shionogi Transformation Strategy 2030 (STS2030) .
Signed the Basic Agreement with Ping An Insurance with a view to building a long-term strategic partnership.
Made Tetra a wholly-owned subsidiary.
Launched the siderophore cephalosporin antibiotic Fetroja (cefiderocol) in the US.
Launched the siderophore cephalosporin antibiotic Fetcroja (cefiderocol) in Europe.